Skip to main content
Premium Trial:

Request an Annual Quote

ImmusanT Raises $20M to Support Celiac Disease CDx, Therapy

NEW YORK (GenomeWeb News) – ImmusanT today announced it has raised $20 million to support further development of its therapy and companion diagnostic and monitoring tool for celiac disease.

The Series A financing comes from venture capital firm Vatera Healthcare Partners and will go toward developing the Cambridge, Mass.-based biotech's immunotherapeutic vaccine Nexvax2 and diagnostics to a proof-of-concept stage. The firm, founded in 2010, said it plans to initiate the next clinical trial in early 2012.

ImmusanT is developing its whole-blood functional T-cell test as a stand-alone diagnostic and as a companion diagnostic for Nexvax2, which combines three peptides that elicit an immune response in patients with celiac disease who carry the immune recognition gene HLA-DQ2. Patients in its clinical trial will be screened with the diagnostic along with standard serology tests to identify those who may benefit the most from Nexvax2, ImmusanT said.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.